证券代码：600267 证券简称：海正药业 公告编号：临 2025-43 号 浙江海正药业股份有限公司 第十届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）第十届董事会第六次会 议于 2025 年 8 月 22 日下午在公司会议室以现场加通讯方式召开。应参加本次会 议董事 9 人，亲自参加会议董事 9 人，公司监事及高管人员列席了会议。本次会 议的召开程序符合《公司法》和《公司章程》的规定，会议合法有效。本次会议 由公司董事长肖卫红先生主持，经与会董事认真讨论研究，会议审议并通过了如 下决议： 一、关于计提资产减值准备的议案； 同意 9 票，反对 0 票，弃权 0 票。 详见《浙江海正药业股份有限公司关于计提资产减值准备的公告》，已登载 于 2025 年 8 月 26 日的《中国证券报》 《上海证券报》 《证券时报》和上海证券交 易所网站（www.sse.com.cn）上。 二、关于前期会计差错更正的议案； 同意 9 票，反对 0 票，弃权 0 票。 本议 ...

Core Viewpoint - Haizheng Pharmaceutical (600267) aims to adopt a differentiated strategy focusing on solidifying its industrial foundation, with emphasis on synthetic biology and high-end manufacturing [1] Group 1: Company Overview - Established in 1956, Haizheng Pharmaceutical started with raw materials and has evolved into a comprehensive pharmaceutical enterprise covering the entire value chain from research and production to sales [1] - The company operates a significant production base in Fuyang, Zhejiang, which spans over 1,500 acres and includes various subsidiaries [1] Group 2: Raw Material Business - The raw material segment is a traditional focus for Haizheng, leveraging technological and production scale advantages [2] - The company has developed over a hundred raw material drug varieties, utilizing a fermentation semi-synthesis technology platform [2] - Haizheng is expanding into the health sector, particularly in medical aesthetics and industrial raw materials, to enhance its sales capabilities [2] Group 3: Production Capabilities - Haizheng has established three major production bases in Taizhou, Fuyang, and Nantong, with a complete production line layout [2] - The Fuyang base features 17 independent production lines and adheres to a production philosophy of "pipeline, closed, continuous, and automated" [2] - The base has successfully secured CMO orders from international giants like Merck and continues to advance new product registrations [2] Group 4: Pharmaceutical Formulation Business - Haizheng has achieved a leading position in exporting injectable drugs to the U.S. market, maintaining high GMP standards [3] - The formulation business is primarily managed by its subsidiary, Hanhui Pharmaceutical, which has developed a unique quality management model [3] - Hanhui has successfully completed technology transfers for several original research products, addressing domestic supply shortages [3] Group 5: Animal Health Sector - The animal health segment is a key area of focus, with Haizheng leveraging its bases to create a diverse product matrix for livestock and pets [3] - Haizheng Animal Health has obtained multiple certifications and has several products with significant sales, including a record-breaking domestic deworming drug [3] - The company has a production capacity of 3,000 acres, allowing for strategic positioning in human and animal pharmaceuticals, both domestically and internationally [3]